Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SINT
SINT logo

SINT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy SINTX Technologies Inc (SINT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.780
1 Day change
3.35%
52 Week Range
6.780
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

SINTX Technologies Inc (SINT) is not a strong buy for a beginner, long-term investor at this moment. While the company has potential due to its innovative biomaterials and a Buy rating from analysts, the financial performance is weak, and there are no significant positive catalysts or trading signals to justify an immediate investment. Holding off for now is advisable.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 49.424, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 2.699, with resistance at 2.924 and support at 2.474.

Positive Catalysts

  • Analyst coverage initiated with a Buy rating and a $10 price target, citing innovative silicon nitride-based biomaterials with strong commercial potential.

Neutral/Negative Catalysts

  • Weak financial performance in Q4 2025, with revenue down 46.49% YoY, EPS down 54.76% YoY, and gross margin declining by 9.44%. No recent news or significant trading trends from insiders or hedge funds.

Financial Performance

In Q4 2025, revenue dropped to $290,000 (-46.49% YoY), net income improved to -$2,215,000 (+30.68% YoY), EPS declined to -0.57 (-54.76% YoY), and gross margin fell to 64.83% (-9.44% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright initiated coverage with a Buy rating and a $10 price target, highlighting the company's potential to disrupt traditional orthopedic implant materials.

Wall Street analysts forecast SINT stock price to rise
1 Analyst Rating
Wall Street analysts forecast SINT stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.690
sliders
Low
16
Averages
16
High
16
Current: 2.690
sliders
Low
16
Averages
16
High
16
H.C. Wainwright
H.C. Wainwright
initiated
$10
AI Analysis
2026-04-13
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10
AI Analysis
2026-04-13
initiated
Reason
H.C. Wainwright initiated coverage of Sintx Technologies with a Buy rating and $10 price target. Sintx is developing silicon nitride-based biomaterials, which offer a \"differentiated combination\" of antimicrobial properties and bone integration that can disrupt traditional orthopedic implant materials, the analyst tells investors in a research note. The firm sees the company entering a \"more relevant\" commercial phase, supported by expanding applications and growing external validation.
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$70 → $30
2025-04-21
Reason
Ascendiant Capital
Edward Woo
Price Target
$70 → $30
2025-04-21
Maintains
Strong Buy
Reason

People Also Watch